AI Article Synopsis
Article Abstract
The accumulation of leukocytes in various tissues contributes to the pathogenesis of numerous human autoimmune diseases. The integrin alpha4beta7, expressed on the surface of B and T lymphocytes, plays an essential role in lymphocyte trafficking throughout the gastrointestinal (GI) tract via interaction with its primary ligand, mucosal addressin cell adhesion molecule (MAdCAM). Elevated MAdCAM expression in the intestines and liver has been linked to GI-associated autoimmune disorders, including Crohn's disease, ulcerative colitis, and hepatitis C. Monoclonal antibodies that block the interaction of alpha4beta7 with MAdCAM inhibit lymphocyte homing to murine intestines without effecting migration to peripheral organs; this suggests that alpha4beta7-selective antagonists might be useful as GI specific antiinflammatory agents. Here, we report the discovery of highly potent and selective alpha4beta7 antagonists affinity selected from a random peptide-phage library. Subsequent optimization of initial peptide leads afforded alpha4beta7-selective heptapeptide inhibitors that competitively inhibit binding to MAdCAM in vitro and inhibit lymphocyte homing to murine intestines in vivo. Substitution of a single carboxylate moiety alters selectivity for alpha4beta7 by more than 500-fold to afford a potent and selective alpha4beta1 antagonist. The antagonists described here are the first peptides to demonstrate potency and selectivity for alpha4beta7 compared to other integrins.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/jm020033k | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: Vedolizumab in Oral Crohn's disease: the downsides of a gut-specific therapy for a multi-site disease.
Front Med (Lausanne)
December 2024
Department of Oral Medicine, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
Introduction: Crohn's disease (CD) is a chronic inflammatory bowel disease which can affect any area of the gastrointestinal tract, including oral tissues. The complex nature of this disease demands interdisciplinary management, especially when both intestinal and oral manifestations are present.
Case: This report presents the case of a 28-year-old male patient with oral, ileo-caecal and peri-anal CD managed jointly between Gastroenterology and Oral Medicine.
Vagal innervation limits brain injury by inhibiting gut-selective integrin-mediated intestinal immunocyte migration in intracerebral hemorrhage.
Theranostics
December 2024
Department of Neurology, The People's Hospital of Zhengzhou University & Henan Provincial People's Hospital, 450003, Zhengzhou, P. R. China.
: The vagus nerve, which connects the brain and gastrointestinal tract, helps to maintain immune balance in the intestines. Gut-specific integrins, on the other hand, help to keep immune cells in the intestines. Since immune cells from outside the intestines can significantly affect the outcome of strokes, we investigated how immune cells from the intestines affect the immune response in the brain during intracerebral hemorrhage (ICH).
View Article and Find Full Text PDFTargeting mucosal healing in Crohn's disease: efficacy of novel pathways and therapeutic targets.
Expert Opin Ther Targets
November 2024
Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital, Milan, Italy.
Introduction: Crohn's disease (CD) is a chronic inflammatory bowel disease affecting the entire gastrointestinal tract with a progressive and relapsing course. Achieving mucosal healing has emerged as a critical therapeutic goal, as it is associated with sustained clinical remission, reduced hospitalizations, and fewer surgery rates. Therefore, targeting mucosal healing is essential for long-term control in CD.
View Article and Find Full Text PDFAssociation Between Vedolizumab Treatment and Arthritis/Arthralgia in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
J Gastrointestin Liver Dis
September 2024
Department of Gastroenterology, CliaGEN, Salvador, Bahia (BA), Brazil.
Background And Aims: Vedolizumab is a humanized gut selective drug that targets α4β7 integrin and has been used successfully in the treatment of inflammatory bowel disease (IBD). Pivotal studies have already demonstrated the drug's safety, but some real-life cohorts have shown an increase in arthralgia and arthritis in patients using vedolizumab. These findings raised the question of whether these joint symptoms are extraintestinal manifestations of IBD (since the drug acts only in the gut) or if they are associated with the use of vedolizumab.
View Article and Find Full Text PDFRecent clinical evidence on nutrition, novel pharmacotherapy, and vaccination in inflammatory bowel diseases.
Front Pharmacol
September 2024
Department of Biochemistry, Faculty of Medicine, University of Medicine and Pharmacy from Craiova, Craiova, Romania.
Article Synopsis
- Inflammatory bowel diseases (IBD), which include Crohn's disease and ulcerative colitis, are chronic conditions with rising global incidence, but their exact causes remain unclear and no definitive cure exists.
- New treatments for IBD, such as vedolizumab and ustekinumab, specifically target immune mediators involved in the disease, with recent monoclonal antibodies showing promise for safety and efficacy.
- The review emphasizes the significance of nutrition, particularly the Western diet, in the onset and progression of IBD while summarizing recent clinical research on diet, drug treatments, and vaccination related to the disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!